FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

WEISER MICHAEL 		2. Issuer Name and Ticker or Trading Symbol

VioQuest Pharmaceuticals, Inc. [ VOQP ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

50 WEST 57TH STREET, 15TH FLOOR 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/13/2008
(Street)

NEW YORK, NY 10019
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.001 par value                  161206   (1) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant   $14.10   (1)                 10/18/2005   10/18/2010   Common Stock, $.001 par value   28000   (1)   28000   (1) D    
Warrant   $4.00   (1)                 6/29/2007   6/29/2012   Common Stock, $.001 par value   657   (1)   657   (1) D    
Series B Convertible Preferred Stock   $3.80   (1)                 3/14/2008     (4) Common Stock, $.001 par value   2781   (1)   10.57   D    
Stock Option   $19.60   (1) 6/13/2008     D  (2)       1290      (2) 10/28/2013   Common Stock, $.001 par value   1290   (1) $0   0   D    
Stock Option   $0.54   6/13/2008     A  (2)    1290         (2) 10/28/2013   Common Stock, $.001 par value   1290   $0   1290   D    
Stock Option   $3.80   6/13/2008     D  (3)       10000      (3) 7/11/2017   Common Stock, $.001 par value   10000   (1) $0   0   D    
Stock Option   $0.54   6/13/2008     A  (3)    10000         (3) 7/11/2017   Common Stock, $.001 par value   10000   $0   10000   D    
Stock Option   $0.54   6/13/2008     A     100000         (5) 6/13/2018   Common Stock, $.001 par value   100000   $0   100000   D    

Explanation of Responses:
( 1)  Adjusted to reflect a 1-for-10 reverse stock split effective on 4/25/2008.
( 2)  This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 10/28/2003 and is fully vested.
( 3)  This transaction involves an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 7/11/2007 and vests in three equal annual installments beginning on 7/11/2007.
( 4)  No expiration date.
( 5)  33,334 shares vest immediately, 33,333 shares vest on each of 6/13/2009 and 6/13/2010.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
WEISER MICHAEL
50 WEST 57TH STREET, 15TH FLOOR
NEW YORK, NY 10019 		X



Signatures
/s/ Michael Weiser 6/18/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
VioQuest Pharmaceuticals (CE) (USOTC:VOQP)
過去 株価チャート
から 11 2024 まで 12 2024 VioQuest Pharmaceuticals (CE)のチャートをもっと見るにはこちらをクリック
VioQuest Pharmaceuticals (CE) (USOTC:VOQP)
過去 株価チャート
から 12 2023 まで 12 2024 VioQuest Pharmaceuticals (CE)のチャートをもっと見るにはこちらをクリック